A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching

Article content

Issued on behalf of Conexeu Sciences Inc.

Article content

Five companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast.

Article content

Article content

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) — World Street Intelligence News Commentary — There are weeks when the most interesting story on Wall Street isn’t a single ticker. It’s the through-line connecting several of them.

Article content

The week of May 21, 2026 was one of those weeks. A brand-new Nasdaq listing in regenerative tissue arrived in the middle of a cluster of earnings beats, pipeline launches, and product approvals across a handful of related names — all of them, in one way or another, telling the same story: medicine is shifting from “replace” to “regenerate,” and the public markets are starting to price that shift in.

Article content

Article content

Here’s the rundown.

Article content

Article content

The New Kid: Conexeu Sciences Inc. (Nasdaq: CNXU)

Article content

The headline event of the week was the debut. Reno, Nevada–based Conexeu Sciences Inc. (Nasdaq: CNXU) commenced trading on the Nasdaq on May 21, 2026, opening its doors to public investors with 25,269,996 shares on an issued and outstanding basis and 35,238,222 shares on a fully diluted basis.

Article content

CEO Miles D. Harrison didn’t open with hedge language. “We believe we are building the biological architecture for a new generation of regenerative medicine designed not simply to replace what has been lost, but to help the body restore itself.”

Article content

That’s the pitch in one line. The substance behind it is a platform called CXU™ — a patented bioregenerative extracellular matrix designed around a single structural principle: one formula, one device, scaling across multiple addressable markets without reformulation. Its first product, Ten Minute Tissue™, is an injectable ECM that remains fluid at room temperature and transitions to a stable gel in situ at body temperature within approximately ten minutes. Its highest-profile pipeline expression, B.R.E.A.S.T.™, is a 3D-bioprinted regenerative breast matrix intended to function as a temporary regenerative scaffold that gradually resorbs as the patient’s own tissue remodels and replaces it over time.

Article content

Article content

The big-market math: more than 100,000 women undergo mastectomies annually in the U.S., yet many elect not to pursue reconstruction. Conexeu is also targeting large, multi-billion-dollar end markets, including wound care, periodontal applications, and facial and body contouring (encompassing GLP-1 driven skin laxity), with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market.

Article content

Status check: preclinical stage. The Company is advancing a predicate-based U.S. regulatory strategy with a 510(k) submission in early 2027 for its initial indication, subject to regulatory review. B.R.E.A.S.T.™ is an investigational medical device candidate. Safety and effectiveness have not been established. It has not been submitted to or reviewed by the U.S. Food and Drug Administration. 

Article content

But the IP is wide and clean. Conexeu holds all rights, title, and interest in the platform IP, with no royalty or licensing obligations and full freedom to expand across new indications and markets. For a brand-new ticker, that’s the kind of starting deck most preclinical names don’t have.